Replies to post #241091 on Amarin Corp Plc (AMRN)

[HDGabor]

g-

Where you read it is their opportunity? It is not more than I quoted: the current market of Vascepa acc. to I- ...

If Hikma could sell gV for all indication (Inc R-IT) they could not make 750M ... they won't own the market .... will not be the biggest ... several other Gs will sell also (Inc Teva)

Best,
G

Ps.: sorry for any typo ... on phone

[HDGabor]

g-

is MARINE indication for non chronic use, i.e., less than 12 weeks, a $750M/year opportunity?

First of all: "less than 12 weeks" is irrelevant, is not a topic at this stage … it was closed weeks / months ago. Generics did not say they will not sell it for more than 12 weeks treatment but they say they will not encourage (by the label) this type of treatment.

(ii) "Current US market size" <> Hikma potential, future, estimated revenue
(iii) the number is the estimation by IQVIA about Amarin / Vascepa revenue
(iv) Hikma - more likely - will not generate $750M from gV ever … generic V market will be significantly lower than V peak sales and 5+ generic will sell it …

SMH … too much ado about nothing

Best,
G